Paper diagnostics market seen reaching $17.31 billion by 2030

The paper diagnostics market is projected to grow from $10.49 billion in 2025 to $17.31 billion by 2030, driven by demand for point-of-care testing, home-based diagnostics and rapid screening tools. North America led the market in 2025, while Asia-Pacific is expected to grow fastest.

Why it matters: - Paper diagnostics are becoming more important as healthcare shifts toward faster, cheaper and more accessible testing. - The market’s growth reflects rising demand for point-of-care, home-based and decentralized diagnostics. - Cardiovascular disease, infectious disease cases and preventive screening needs are expanding use cases for rapid paper-based tests.

What happened: - The paper diagnostics market was valued at $10.49 billion in 2025. - The market is projected to reach $11.62 billion in 2026. - The market is forecast to hit $17.31 billion by 2030. - The Business Research Company projects a 10.7% CAGR from 2025 to 2026 and a 10.5% CAGR through 2030. - The company released the market update on Aug. 21, 2026.

The details: - Growth is being driven by point-of-care testing demand, more infectious disease cases, decentralized healthcare models and wider use of dipstick diagnostics. - Home-based diagnostic options are gaining favor with patients and healthcare providers. - Investments in affordable healthcare technologies are widening access, especially in low-resource settings. - Preventive healthcare and early disease detection are pushing adoption of screening programs and routine monitoring. - Paper microfluidics technology is making paper-based diagnostic devices more sophisticated and improving speed and accuracy. - Paper diagnostics use cellulosic and paper materials to detect and quantify chemicals or biological molecules tied to health assessments. - These devices are used in hospitals, clinics, sports testing facilities and maternity wards. - Their low cost, portability and simplicity make them suitable for a wide range of tests. - Microfluidic paper-based devices can identify multiple cardiac biomarkers at once, supporting early and late-stage diagnosis of acute myocardial infarction. - Data from the American Heart Association showed the U.S. age-adjusted cardiovascular death rate rose to 233.3 per 100,000 in January 2024 from 224.4 per 100,000 in 2023, a 4.0% increase. - North America held the largest share of the paper diagnostics market in 2025. - Asia-Pacific is expected to be the fastest-growing region. - The report also covers South East Asia, Western Europe, Eastern Europe, South America, the Middle East and Africa. - The 2026 report suite includes market attractiveness scoring, TAM analysis, a company scoring matrix, Excel forecasting dashboards, market hotspots infographics and updated graphics and tables. - The company offered a free sample and the full report through linked pages: Download a free sample of the paper diagnostics market report and View the full paper diagnostics market report.

Between the lines: - The forecast suggests paper diagnostics are moving from niche testing toward broader frontline use. - The regional split points to mature adoption in North America and faster expansion where healthcare access is still improving. - The cardiovascular data helps explain why rapid biomarker testing remains a commercial and clinical priority.

What's next: - The market is expected to keep expanding as healthcare systems look for lower-cost and more portable testing options. - Wider adoption of rapid screening and decentralized care could support continued growth beyond 2030. - More development in paper microfluidics may improve test performance and expand clinical applications.

The bottom line: - Paper diagnostics are on track for sustained double-digit growth, with demand tied to convenience, affordability and faster disease detection.